STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Johnson & Johnson insider plans $22.65M sale via Fidelity on NYSE

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Johnson & Johnson (JNJ) filed a Form 144 reporting a proposed sale of 125,824 common shares through Fidelity Brokerage Services with an aggregate market value of $22,652,723.84. The filing states the shares are to be sold on or about 08/22/2025 and that the shares were acquired via an option granted on 02/08/2016, with payment to be cash at sale.

The filer certifies there is no undisclosed material information and indicates no other securities of the issuer were sold by the same person in the past three months. The disclosure documents a sizable, rule-compliant planned insider sale routed through a broker on the NYSE.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Routine, transparent insider sale of 125,824 shares totaling ~$22.7M; neutral but notable for size.

The Form 144 shows an insider selling shares acquired by option exercise in 2016, using Fidelity as broker and receiving cash at sale. The transaction is a standard Rule 144 notification and the filer affirms no material nonpublic information. For investors, the key datapoints are the number of shares and the aggregate value; absent other context about holdings or intent, this disclosure is a neutral liquidity event rather than an operational signal.

TL;DR: Disclosure meets Rule 144 requirements; representation of no undisclosed material info is important for compliance.

The filing documents compliance with securities-law disclosure norms and includes the required representation about material information and any 10b5-1 trading plans. The use of a broker and explicit acquisition details (option grant date) support traceability. This is a governance-positive action insofar as it provides public notice of an insider sale.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Johnson & Johnson

NYSE:JNJ

JNJ Rankings

JNJ Latest News

JNJ Latest SEC Filings

JNJ Stock Data

485.76B
2.41B
0.06%
74.37%
0.78%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
NEW BRUNSWICK